Jesús San Miguel, MD, Universidad de Navarra, Navarra, Spain, discusses the results of extended follow up of daratumumab-based regimens in transplant-ineligible newly diagnosed multiple myeloma patients. The Phase III MAIA trial (NCT02252172) and the ALCYONE trial (NCT02195479) investigated the addition of the anti-CD38 monoclonal antibody, daratumumab (DARA), to the standard of care regimens lenalidomide plus dexamethasone (D-Rd) and bortezomib plus melphalan plus prednisone (D-VMP) respectively. Long-term follow-up found that in both trials DARA addition improved minimal residual disease (MRD) negativity compared to the standard of care. More patients achieved sustained MRD negativity for ≥6 months and ≥12 months and progression-free survival (PFS) was prolonged in these patients compared to those without sustained MRD negativity. These results are suggestive of improved responses with the addition of DARA in newly diagnosed multiple myeloma. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.